Basilea preps key US filing for MRSA antibiotic ceftobiprole

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.<